Fromstein SR, Harthan JS, Patel J, et al. Demodex blepharitis: clinical perspectives. Clin. Optom. 2018;10:57–63.

Article  Google Scholar 

Rhee MK, Yeu E, Barnett M, et al. Demodex blepharitis: a comprehensive review of the disease, current management, and emerging therapies. Eye Contact Lens. 2023;49(8):311–8.

Article  PubMed  PubMed Central  Google Scholar 

Farid M, Ayres BD, Donnenfeld E, et al. Delphi panel consensus regarding current clinical practice management options for Demodex blepharitis. Clin Ophthalmol. 2023;17:667–79.

Article  PubMed  PubMed Central  Google Scholar 

Tarsus Pharmaceuticals. FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis [media release]. 25 Jul 2023. https://ir.tarsusrx.com/news-releases/news-release-details/fda-approves-xdemvytm-lotilaner-ophthalmic-solution-025.

Tarsus Pharmaceuticals. XDEMVY™ (lotilaner ophthalmic solution) 0.25%, for topical ophthalmic use: US prescribing information. 2023. https://tarsusrx.com/wp-content/uploads/XDEMVY-Prescribing-Information-24JUL23.pdf. Accessed 28 Aug 2023.

Zhou X, Hohman AE, Hsu WH. Current review of isoxazoline ectoparasiticides used in veterinary medicine. J Vet Pharmacol Ther. 2022;45(1):1–15.

Article  PubMed  Google Scholar 

Ozoe Y, Asahi M, Ozoe F, et al. The antiparasitic isoxazoline A1443 is a potent blocker of insect ligand-gated chloride channels. Biochem Biophys Res Commun. 2010;391(1):744–9.

Article  CAS  PubMed  Google Scholar 

Gonzalez-Salinas R, Yeu E, Holdbrook M, et al. Safety and efficacy of topical lotilaner ophthalmic solution 0.25% for the treatment of Demodex blepharitis: a pilot study. J Ophthalmol. 2021. https://doi.org/10.1155/2021/3862684.

Article  PubMed  PubMed Central  Google Scholar 

Gonzalez-Salinas R, Yeu E, Holdbrook M, et al. Collarette elimination and Demodex mite eradication with topical lotilaner ophthalmic solution, 0.25. J Ocul Pharmacol Ther. 2021;37(8):479–84.

Article  CAS  PubMed  Google Scholar 

Gonzalez-Salinas R, Karpecki P, Yeu E, et al. Safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to Demodex infestation: a randomized, controlled, double-masked clinical trial. Cont Lens Anterior Eye. 2022;45(4):101492.

Article  PubMed  Google Scholar 

Yeu E, Holdbrook M, Baba SN, et al. Treatment of Demodex blepharitis: a prospective, randomized, controlled, double-masked clinical trial comparing topical lotilaner ophthalmic solution, 0.25% eyedrops to vehicle. Ocul Immunol Inflamm. 2022. https://doi.org/10.1080/09273948.2022.2093755.

Article  PubMed  Google Scholar 

Yeu E, Wirta DL, Karpecki P, et al. Lotilaner ophthalmic solution, 0.25%, for the treatment of Demodex blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1). Cornea. 2023;42(4):435–43.

Article  PubMed  Google Scholar 

Gaddie IB, Donnenfeld ED, Karpecki P, et al. Lotilaner ophthalmic solution 0.25% for Demodex blepharitis: randomized, vehicle-controlled, multicenter, phase 3 trial (Saturn-2). Ophthalmology. 2023. https://doi.org/10.1016/j.ophtha.2023.05.030.

Article  PubMed  Google Scholar 

Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005;46(9):3089–94.

Article  PubMed  Google Scholar 

Sadri E, Castillo RM, Jalalat P. Long term safety of lotilaner ophthalmic solution, 0.25% for the treatment of Demodex blepharitis: Saturn 1 extension study [slide deck]. In: American Society of Cataract and Refractive Surgery Annual Meeting. 2023.